Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 4.83B |
| Revenue (ttm) | 45.34M |
| Net Income (ttm) | -400.43M |
| Shares Out | 76.01M |
| EPS (ttm) | -5.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,118,715 |
| Open | 63.97 |
| Previous Close | 63.32 |
| Day's Range | 61.83 - 64.95 |
| 52-Week Range | 37.08 - 180.59 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 131.26 (+106.7%) |
| Earnings Date | Aug 4, 2022 |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on... [Read more...]
Financial Performance
In 2021, NTLA's revenue was $33.05 million, a decrease of -43.01% compared to the previous year's $57.99 million. Losses were -$267.89 million, 99.6% more than in 2020.
Financial StatementsAnalyst Forecast
According to 30 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 131.26, which is an increase of 106.74% from the latest price.
News
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editin...
Why Intellia Therapeutics Stock Is Sinking Today
Investors are reacting negatively to the company's Q2 update.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies levera...
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics lev...
2 Biotech Stocks You'll Regret Not Buying on the Dip
BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...
Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High
Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of...
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simula...
BMO Initiates Coverage On This Gene Editing Spearhead
BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliv...
5 Health Care Stocks Cathie Wood Favors
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatm...
CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-bas...
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-base...
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-b...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platfo...
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-base...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics le...
3 Top Biotech Stocks Ready for a Bull Run
The hype has died down. Now it's time for science to take over.
3 Ominous Reasons to Avoid This Biotech Pioneer
They point to trouble for investors counting on a rebound.
Thanks To These CRISPR Stocks, The Path To Rewriting Human DNA Is About To Get Pretty Fierce
Experts say CRISPR-based treatments could soon constitute a massive market — and the prospects are grabbing Big Pharma's attention. Investor's Business Daily has been helping people invest smarter resul...